What Pharm-Olam does

Pharm-Olam is a multi-national contract research organization (CRO) headquartered in Houston, Texas, founded in 1994. The company operates with 501-1,000 employees and serves as a full-service clinical development partner to pharmaceutical and biotechnology sponsors, executing clinical trials across multiple geographies. Its service offering spans the core CRO value chain — clinical trial management, biostatistics, regulatory support, and data services — with the 2011 acquisition of StatWorks, inc. specifically adding biostatistics and statistical programming depth to its capability set.

Pharm-Olam monetizes through professional-services contracts with biopharma sponsors, a model typical of mid-size CROs where revenue is tied to per-study fees, milestone payments, and multi-year managed-service engagements. The firm was founded by Zev Munk (now Chairman) and Eugene Barg, with co-founder continuity in governance more than three decades after incorporation. In 2017 the company received an investment round led by Quad-C Management, a lower middle-market private equity firm, signaling an active growth-equity phase aimed at scaling therapeutic breadth and geographic reach.

Data on Pharm-Olam's specific customer roster, product-level pricing, recent revenue, AI/technology stack, and post-2017 strategic activity is limited in the available source material. The firm should be viewed as a privately held, PE-backed mid-market CRO with three decades of operating history, a multi-national footprint, and demonstrated inorganic capability build (StatWorks), but with observable performance gaps that limit confident forward extrapolation.

Name

Pharm-Olam

Legal name

Allucent

Website

https://pharm-olam.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Pharm-Olam is a privately held, multi-national contract research organization (CRO) founded in 1994 and headquartered in Houston, serving pharmaceutical and biotechnology sponsors with full-service clinical trial management, biostatistics, and regulatory support across multiple geographies.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Pharmacology & Pharmacometrics (Modeling & Simulation) (HLAIALAG)

akta.pro secondary industry

Clinical Trial Pharmacy & IMP Management at Site (HLAGACAK)

Keywords

• Contract research organization
• Clinical development services
• Clinical pharmacology
• Regulatory strategy
• Pharmacovigilance services

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Contract Research Organization Services: Full-service CRO services spanning clinical development, clinical pharmacology, regulatory strategy, and drug safety/pharmacovigilance. Revenue generated through service contracts with biotech sponsors across all trial phases.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Pharm-Olam is a multi-national contract research organization that delivers full-service clinical research and drug development support to small and mid-sized biotech companies. Services span clinical development (study start-up, site intelligence, patient recruitment, decentralized trials, data management, biostatistics, medical monitoring), clinical pharmacology (drug development strategy, modeling & simulation, pharmacokinetics, embedded pharmacologist), regulatory strategy (CMC, clinical strategy, biostatistical consulting, submissions, GxP consulting), and drug safety/pharmacovigilance, including government and public health programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Development Services

Quantifiable outcome

• 825+ annual regulatory submissions
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators10 records

Recent moves3 records

Expansion highlights3 records

Direct peers

• Medpace Holdings: Medpace is a mid-size, full-service CRO focused on small and mid-sized biotech sponsors — a near-perfect direct peer to Pharm-Olam in customer segment, service model, and scale.
• Parexel International: Parexel is a mid-to-large CRO with a strong biotech sponsor book and deep therapeutic expertise. Following its 2021 PE take-private by EQT and Goldman Sachs, it is a private-market comp for Pharm-Olam.
• Allucent: Allucent is a global full-service CRO that focuses on small and mid-sized biotech sponsors — a near-identical target customer and service mix to Pharm-Olam. Notably, a large portion of the provided data set appears to have been pulled from Allucent's site, suggesting either a prior relationship, a data conflation issue, or co-marketing between the two firms.
• Syneos Health: Syneos is a full-service biopharma solutions organization combining CRO services with commercial capabilities. It is one of the most direct competitors to Pharm-Olam for full-service biotech clinical development work.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size CRO with strong CNS, cardiometabolic, and rare disease capabilities. It competes head-to-head with Pharm-Olam for mid-sized biotech full-service engagements.
• Premier Research: Premier Research is a mid-size CRO with a biotech-focused book and depth in oncology, rare disease, and pediatric trials. It is comparable to Pharm-Olam in customer profile, scale, and PE-backed ownership history.

Broad incumbents

• Labcorp Drug Development (formerly Covance): Labcorp Drug Development is a top-tier CRO with integrated central lab and early-development services. Its scale and lab-embedded offering set the competitive ceiling for mid-size peers like Pharm-Olam.
• ICON plc: ICON is a top-3 global CRO offering full-service clinical development, with particularly strong capabilities in labs, data, and post-approval research following the PRA Health Sciences merger. It competes directly with Pharm-Olam for multi-region biotech trial mandates.
• IQVIA: IQVIA is the world's largest CRO, offering full-service clinical development, real-world evidence, and advanced analytics. It is a broad incumbent against which all mid-tier CROs like Pharm-Olam compete, particularly for large pharma preferred-provider contracts.
• Charles River Laboratories: Charles River is a leading CRO with strong early-stage and discovery services, expanding into clinical through its 2021 PRA Health combination. It competes with Pharm-Olam for biotech sponsors needing integrated early-to-clinical development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• YouTubeyoutube.com/@allucent
• LinkedInlinkedin.com/company/pharm-olam-international
• Xx.com/pharm_olam

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharm-Olam